

Corrections

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, and Ollendorf DA. *J Manag Care Spec Pharm.* 2018;24(1):29-38.

The authors would like to make the following corrections to the above article:

Page 31, Table 1: The progression-free survival hazard ratio estimate for PAN+BOR+DEX versus LEN+DEX was corrected. Corrections are shown in bold below:

Third-line PFS hazard ratios vs. LEN-DEX					
BOR-DEX	0.93	0.58	2.04	LogNormal	Network meta-analysis
CFZ-LEN-DEX	0.69	0.54	0.87	LogNormal	Network meta-analysis
ELO-LEN-DEX	0.70	0.49	0.87	LogNormal	Network meta-analysis
IX-LEN-DEX	0.74	0.40	0.84	LogNormal	Network meta-analysis
PAN-BOR-DEX	0.59	0.31	1.10	LogNormal	Network meta-analysis
DAR-LEN-DEX ^a	0.37	0.27	0.52	LogNormal	Network meta-analysis
DAR-BOR-DEX ^a	0.39	0.28	0.53	LogNormal	Network meta-analysis

Page 31, Table 1: Estimated drug costs were updated. Corrections are shown in bold below:

Costs	Base Case	Lower	Upper	PSA Distribution	Source
Drug acquisition and administration costs,^c \$					
Bortezomib 3.5 mg vial	1,503.00	1,202.40	1,803.60	Normal	RED BOOK
Bortezomib administration	111.42	89.14	133.70	Normal	CPT 96409
Carfilzomib 60 mg vial	1,971.50	1,577.20	2,365.80	Normal	RED BOOK
Carfilzomib administration	209.24	167.39	251.09	Normal	CPT 96360, 96361, 96413
Dexamethasone per mg	0.32	0.26	0.39	Normal	RED BOOK
Elotuzumab 300 mg vial	1,776.00	1,420.80	2,131.20	Normal	RED BOOK
Elotuzumab 400 mg vial	2,368.00	1,894.40	2,841.60	Normal	RED BOOK
Elotuzumab administration	227.87	182.30	273.44	Normal	CPT 96413, 96415, 96417
Ixazomib capsule	3,006.00	2,404.80	3,607.20	Normal	RED BOOK
Lenalidomide capsule	552.98	442.38	663.58	Normal	RED BOOK
Panobinostat capsule	1,222.22	977.78	1,466.67	Normal	RED BOOK
Daratumumab 400 mg vial	1,850.40	1,480.32	2,220.48	Normal	RED BOOK
Daratumumab 100 mg vial	462.60	370.08	555.12	Normal	RED BOOK
Daratumumab administration	399.83	319.86	479.80	Normal	CPT 96413, 96415, 96417

Page 33, Table 2: Comparative estimates in the Third Line section have been changed for PAN+BOR+DEX, as shown in bold below:

TABLE 2 Comparative Outcomes									
Regimen	Second Line			Third Line (All Comparators)			Third Line (PAN-BOR-DEX Omitted)		
	Total Cost, \$	QALYs	ICER	Total Cost, \$	QALYs	ICER	Total Cost, \$	QALYs	ICER
LEN-DEX	309,997	2.59	Dominated	281,754	2.04	Dominated	281,754	2.04	Dominated
BOR-DEX	189,357	2.74	Dominant	175,315	2.16	Dominant	175,315	2.16	Dominant
IX-LEN-DEX	622,378	3.27	Dominated	566,512	2.60	Dominated	566,512	2.60	Dominated
ELO-LEN-DEX	665,728	3.41	Dominated	608,651	2.71	Dominated	608,651	2.71	Dominated
CFZ-LEN-DEX	492,872	3.45	Dominated	459,868	2.74	Dominated	459,868	2.74	Dominated
PAN-BOR-DEX				190,876	3.23	14,598			
DAR-BOR-DEX	447,182	5.29	50,704	423,119	4.38	248,762	423,119	4.38	60,359
DAR-LEN-DEX	845,527	5.44	2,707,547	789,202	4.38	Equal outcomes, higher cost vs. DAR-BOR-DEX	789,202	4.38	Equal outcomes, higher cost vs. DAR-BOR-DEX


BOR = bortezomib; CFZ = carfilzomib; DAR = daratumumab; DEX = dexamethasone; ELO = elotuzumab; ICER = incremental cost-effectiveness ratio; IX = ixazomib; LEN = lenalidomide; OS = overall survival; PAN = panobinostat; PFS = progression-free survival; QALY = quality-adjusted life-year.

Corrections

Page 34, Table 3: In the Third Line section, comparative estimates have been changed for PAN+BOR+DEX, as shown in bold below:

Third Line	LEN-DEX	BOR-DEX	CFZ-LEN-DEX	ELO-LEN-DEX	IX- LEN-DEX	PAN-BOR-DEX	DAR-LEN-DEX	DAR-BOR-DEX
Total costs, \$	281,754	175,315	459,868	608,651	566,512	190,876	789,202	423,119
Drug acquisition	237,670	121,751	401,201	541,632	516,793	131,500	707,051	344,684
Supportive care	473	1,441	1,779	2,364	2,255	411	4,579	2,403
Administration		7,365	8,113	13,394	–	3,095	22,394	21,412
Progression	39,261	40,175	44,318	44,105	43,298	46,744	51,708	52,014
Adverse event	4,351	4,583	4,457	7,156	4,166	9,127	3,469	2,607
Total QALYs	2.04	2.16	2.74	2.71	2.60	3.23	4.38	4.38
PFS	1.00	1.07	1.37	1.36	1.30	1.69	2.28	2.35
Progression	1.03	1.09	1.37	1.36	1.30	1.54	2.10	2.03
Total life-years (OS)	3.25	3.44	4.37	4.32	4.14	4.93	6.97	6.71
PFS	1.55	1.64	2.12	2.09	2.00	2.41	3.52	3.38
Progression	1.70	1.79	2.25	2.23	2.14	2.52	3.44	3.33
ICER vs. LEN-DEX	–	-853,800	252,293	484,168	508,021	Dominant	216,360	60,359

Page 35, Figure 1: Third Line graph was updated to reflect a new cost-effectiveness acceptability curve, as shown below:



Page 36, Table 4: Changes were made to drug cost thresholds for PAN+BOR+DEX in the Third Line section, as shown below in bold:

TABLE 4 Drug Cost Thresholds						
WTP Threshold	Second Line, \$			Third Line, \$		
	50,000	100,000	150,000	50,000	100,000	150,000
CFZ-LEN-DEX	55 (-906-1,063)	649 (-68-1,733)	1,242 (405-2,661)	0 (-938-622)	445 (-633-1,518)	946 (-386-2,417)
ELO-LEN-DEX	-69 (-535-619)	252 (-141-903)	572 (138-1,272)	-126 (-644-484)	162 (-266-692)	449 (34-1,032)
IX-LEN-DEX	-278 (-903-567)	127 (-294-830)	533 (84-1,329)	-347 (-1,046-593)	19 (-502-769)	385 (-40-1,180)
PAN-BOR-DEX				3,459 (2,389-5,552)	4,344 (2,668-8,242)	5,229 (2,792-10,987)
DAR-LEN-DEX	-165 (-779-486)	567 (-51-1,239)	1,298 (614-2,093)	-293 (-902-417)	351 (-239-1,080)	995 (338-1,800)
DAR-BOR-DEX	1,840 (1,495-2,278)	2,582 (2,139-3,050)	3,324 (2,674-3,976)	1,708 (1,374-2,114)	2,397 (1,948-2,959)	3,087 (2,479-3,845)

Note: Results reflect threshold prices for the first listed drug in each triplet regimen only (all other parameter values held constant).

BOR = bortezomib; CFZ = carfilzomib; DAR = daratumumab; DEX = dexamethasone; ELO = elotuzumab; IX = ixazomib; LEN = lenalidomide; PAN = panobinostat; WTP = willingness to pay.

Page 36, second column, last paragraph, second sentence, is changed to the following:

“First, the independently modeled PFS and OS curves in the Jakubowiak et al. analysis yielded much more favorable estimates of treatment effect for CFZ+LEN+DEX than those reported in the ASPIRE trial versus LEN+DEX (PFS odds ratio=0.51 [model] vs. 0.69 [published hazard ratio]; OS hazard ratio=0.70 [model] vs. 0.79 [published hazard ratio]).”

Page 37, top paragraph, last sentence, is changed to the following:

“Finally, we note that 1 of the findings of the Jakubowiak et al. analysis appears to be counterintuitive, in that CFZ+LEN+DEX patients spend approximately 4 years in the postprogression state in the model versus approximately 3 years for LEN+DEX; however, the postprogression treatment costs for LEN+DEX are reported to be higher.”

While the authors regret these errors, they do not affect the conclusions of the study.